Find the latest pharmaceutical market place for APIs enquiry about Eravacycline on PharmaCompass.com.

Various APIs needed in Egypt [ENA14754]

A company operating in the pharmaceutical field for the development, manufacturing, marketing, distribution and export of a comprehensive array of branded and generic drugs is looking for suppliers of Various APIs for evaluation purpose. The suppliers must support this enquiry with GMP & CoA.
1. Cefiderocol API
2. Ceftobiprole API
3. Eravacycline API
4. Omadacycline API
5. Plazomicin Sulfate API

Reply

20 Aug 2022

Various APIs needed in Egypt [ENA13457]

An Egyptian company that deals in various pharmaceutical products is looking for suppliers of Various APIs. The required quantity is 1 kg for each.
1. Sterile Grade Plazomicin Sulfate API
2. Sterile Grade Omadacycline Tosylate API
3. Sterile Grade Eravacycline API

Reply

27 Apr 2022

Bangladesh Flag

Eravacycline and Lefamulin Acetate APIs needed in Bangladesh [ENA06178]

A leading pharmaceutical company in Bangladesh is looking for suppliers of Eravacycline and Lefamulin Acetate APIs for developmental purposes. The suppliers must support this enquiry with CoA.

Reply

30 Dec 2019

Bangladesh Flag

Injectable Grade Eravacycline API needed in Bangladesh [ENA05686]

A pharmaceutical company in Bangladesh renowned as manufacturers is looking for suppliers of Injectable Grade Eravacycline API. The supplier must support this enquiry with DMF, GMP & CoA.

Reply

06 Nov 2019

india-flag Flag

Injectable grade Eravacycline, Caffeine Citrate and other APIs needed in India [ENA01959]

Orbit Corporation is a rapidly growing organisation based in India. The company is looking for suppliers of Injectable grade Eravacycline, Caffeine Citrate and Antihaemophilic Factor. Interested suppliers must support this enquiry with the following specifications:
1) Certificate of Analysis (COA)
2) GMP certificate
3) Open Part of DMF
4) CEP
The suppliers must contact Md. Shahidul Islam SABUJ via E-mail: sabuj.orbit@gmail.com or Tel: 01716005198.

Reply

18 Sep 2018